Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed

American Journal of Medicine

Volumn 129, Issue 11, 2016, Pages S54-S63

  Milling, Truman J ^a   Spyropoulos, Alex C ^b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

Direct acting oral anticoagulants; Gastrointestinal bleeding; Intracranial hemorrhage; Major hemorrhage; Restart oral anticoagulants; Warfarin

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; ANTITHROMBIN; APIXABAN; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; RIVAROXABAN;

ANTICOAGULANT THERAPY; ARTICLE; BRAIN HEMORRHAGE; CLINICAL DECISION MAKING; GASTROINTESTINAL HEMORRHAGE; HUMAN; PRIORITY JOURNAL; RETREATMENT; RISK ASSESSMENT; ATRIAL FIBRILLATION; BLEEDING; CHEMICALLY INDUCED; COMPLICATION; RECURRENT DISEASE; STROKE; THROMBOEMBOLISM;

ANTITHROMBINS; ATRIAL FIBRILLATION; DABIGATRAN; FACTOR XA INHIBITORS; GASTROINTESTINAL HEMORRHAGE; HEMORRHAGE; HUMANS; INTRACRANIAL HEMORRHAGES; PYRAZOLES; PYRIDONES; RECURRENCE; RISK ASSESSMENT; RIVAROXABAN; STROKE; THROMBOEMBOLISM;

EID: 84992488218     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2016.06.006     Document Type: Article

References (70)

1. 1 Chugh, S.S., Havmoeller, R., Narayanan, K., et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 129 (2014), 837–847.
2. 2 IMS Health. Medicine use and shifting costs of healthcare: a review of the use of medicines in the United States in 2013. Available at: http://www.imshealth.com/en/thought-leadership/ims-institute/reports/use-of-medicines-in-the-us-2013. Accessed July 22, 2016.
3. 3 Ogilvie, I.M., Newton, N., Welner, S.A., Cowell, W., Lip, G.Y., Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 123:7 (2010), 638e4–645e4.
4. 4 You, J.J., Singer, D.E., Howard, P.A., et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141 (2012), e531S–e575S.
5. 5 Camm, A.J., Lip, G.Y., De Caterina, R., et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33 (2012), 2719–2747.
6. 6 January, C.T., Wann, L.S., Alpert, J.S., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 130 (2014), 2071–2104.
7. 7 Fitch, K., Broulette, J., Pyenson, B., Iwasaki, K., Kwong, W.J., Utilization of anticoagulation therapy in medicare patients with nonvalvular atrial fibrillation. Am Health Drug Benefits 5 (2012), 157–168.
8. 8 Sen, S., Dahlberg, K.W., Physician's fear of anticoagulant therapy in nonvalvular atrial fibrillation. Am J Med Sci 348 (2014), 513–521.
9. 9 Cervera, A., Amaro, S., Chamorro, A., Oral anticoagulant-associated intracerebral hemorrhage. J Neurol 259 (2012), 212–224.
10. 10 Wiedermann, C.J., Stockner, I., Warfarin-induced bleeding complications – clinical presentation and therapeutic options. Thromb Res 122:suppl 2 (2008), S13–S18.
11. 11 Schulman, S., Beyth, R.J., Kearon, C., Levine, M.N., American College of Chest Physicians. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:6 suppl (2008), 257S–298S.
12. 12 Pugh, D., Pugh, J., Mead, G.E., Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. Age Ageing 40 (2011), 675–683.
13. 13 Schulman, S., Kearon, C., Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3 (2005), 692–694.
14. 14 Hylek, E.M., Evans-Molina, C., Shea, C., Henault, L.E., Regan, S., Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115 (2007), 2689–2696.
15. 15 Connolly, S.J., Ezekowitz, M.D., Yusuf, S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 (2009), 1139–1151.
16. 16 Patel, M.R., Mahaffey, K.W., Garg, J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365 (2011), 883–891.
17. 17 Granger, C.B., Alexander, J.H., McMurray, J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365 (2011), 981–992.
18. 18 Giugliano, R.P., Ruff, C.T., Braunwald, E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369 (2013), 2093–2104.
19. 19 Schulman, S., Kearon, C., Kakkar, A.K., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361 (2009), 2342–2352.
20. 20 Bauersachs, R., Berkowitz, S.D., Brenner, B., et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363 (2010), 2499–2510.
21. 21 Agnelli, G., Buller, H.R., Cohen, A., et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369 (2013), 799–808.
22. 22 Büller, H.R., Décousus, H., Grosso, M.A., et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369 (2013), 1406–1415.
23. 23 Heidbuchel, H., Verhamme, P., Alings, M., et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 17 (2015), 1467–1507.
24. 24 Hofmeijer, J., Kappelle, L.J., Klijn, C.J., Antithrombotic treatment and intracerebral haemorrhage: between Scylla and Charybdis. Pract Neurol 15 (2015), 250–256.
25. 25 van Asch, C.J., Luitse, M.J., Rinkel, G.J., van der Tweel, I., Algra, A., Klijn, C.J., Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol 9 (2010), 167–176.
26. 26 Flaherty, M.L., Anticoagulant-associated intracerebral hemorrhage. Semin Neurol 30 (2010), 565–572.
27. 27 Kuramatsu, J.B., Gerner, S.T., Schellinger, P.D., et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 313 (2015), 824–836.
28. 28 Nielsen, P.B., Larsen, T.B., Skjøth, F., Gorst-Rasmussen, A., Rasmussen, L.H., Lip, G.Y., Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding: a nationwide cohort study. Circulation 132 (2015), 517–525.
29. 29 Yung, D., Kapral, M.K., Asllani, E., Fang, J., Lee, D.S., Investigators of the Registry of the Canadian Stroke Network. Reinitiation of anticoagulation after warfarin-associated intracranial hemorrhage and mortality risk: the Best Practice for Reinitiating Anticoagulation Therapy After Intracranial Bleeding (BRAIN) study. Can J Cardiol 28 (2012), 33–39.
30. 30 Majeed, A., Kim, Y.K., Roberts, R.S., Holmström, M., Schulman, S., Optimal timing of resumption of warfarin after intracranial hemorrhage. Stroke 41 (2010), 2860–2866.
31. 31 Aguilar, M.I., Hart, R.G., Kase, C.S., et al. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc 82 (2007), 82–92.
32. 32 Hawryluk, G.W., Austin, J.W., Furlan, J.C., Lee, J.B., O'Kelly, C., Fehlings, M.G., Management of anticoagulation following central nervous system hemorrhage in patients with high thromboembolic risk. J Thromb Haemost 8 (2010), 1500–1508.
33. 33 Phan, T.G., Koh, M., Wijdicks, E.F., Safety of discontinuation of anticoagulation in patients with intracranial hemorrhage at high thromboembolic risk. Arch Neurol 57 (2000), 1710–1713.
34. 34 Hippisley-Cox, J., Coupland, C., Predicting risk of upper gastrointestinal bleed and intracranial bleed with anticoagulants: cohort study to derive and validate the QBleed scores. BMJ, 349, 2014, g4606.
35. 35 Chai-Adisaksopha, C., Crowther, M., Isayama, T., Lim, W., The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood 124 (2014), 2450–2458.
36. 36 Sengupta, N., Feuerstein, J.D., Patwardhan, V.R., et al. The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study. Am J Gastroenterol 110 (2015), 328–335.
37. 37 Qureshi, W., Mittal, C., Patsias, I., et al. Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. Am J Cardiol 113 (2014), 662–668.
38. 38 Witt, D.M., Delate, T., Garcia, D.A., et al. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med 172 (2012), 1484–1491.
39. 39 Chai-Adisaksopha, C., Hillis, C., Monreal, M., Witt, D.M., Crowther, M., Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding. A meta-analysis. Thromb Haemost 114 (2015), 819–825.
40. 40 Salem, D.N., O'Gara, P.T., Madias, C., Pauker, S.G., American College of Chest Physicians. Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 (2008), 593S–629S.
41. 41 Gage, B.F., Waterman, A.D., Shannon, W., Boechler, M., Rich, M.W., Radford, M.J., Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285 (2001), 2864–2870.
42. 42 Douketis, J.D., Crowther, M.A., Foster, G.A., Ginsberg, J.S., Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis?. Am J Med 110 (2001), 515–519.
43. 43 Lobo, J.L., Jimenez, D., Teresa Orue, M., et al. Recurrent venous thromboembolism during coumarin therapy. Data from the computerised registry of patients with venous thromboembolism. Br J Haematol 138 (2007), 400–403.
44. 44 Carrier, M., Le Gal, G., Wells, P.S., Rodger, M.A., Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 152 (2010), 578–589.
45. 45 Douketis, J.D., Gu, C.S., Schulman, S., Ghirarduzzi, A., Pengo, V., Prandoni, P., The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med 147 (2007), 766–774.
46. 46 Longstreth, W.T. Jr., Bernick, C., Fitzpatrick, A., et al. Frequency and predictors of stroke death in 5,888 participants in the Cardiovascular Health Study. Neurology 56 (2001), 368–375.
47. 47 Linkins, L.A., Choi, P.T., Douketis, J.D., Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 139 (2003), 893–900.
48. 48 Deviri, E., Sareli, P., Wisenbaugh, T., Cronje, S.L., Obstruction of mechanical heart valve prostheses: clinical aspects and surgical management. J Am Coll Cardiol 17 (1991), 646–650.
49. 49 Arboix, A., Alio, J., Acute cardioembolic cerebral infarction: answers to clinical questions. Curr Cardiol Rev 8 (2012), 54–67.
50. 50 Steiner, T., Kaste, M., Forsting, M., et al. Recommendations for the management of intracranial haemorrhage - part I: spontaneous intracerebral haemorrhage. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee. Cerebrovasc Dis 22 (2006), 294–316.
51. 51 Hemphill, J.C. 3rd, Greenberg, S.M., Anderson, C.S., et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 46 (2015), 2032–2060.
52. 52 Lansberg, M.G., O'Donnell, M.J., Khatri, P., et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141 (2012), e601S–e636S.
53. 53 Kernan, W.N., Ovbiagele, B., Black, H.R., et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 45 (2014), 2160–2236.
54. 54 Lip, G.Y., Nieuwlaat, R., Pisters, R., Lane, D.A., Crijns, H.J., Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137 (2010), 263–272.
55. 55 Piccini, J.P., Stevens, S.R., Chang, Y., et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation 127 (2013), 224–232.
56. 56 Hippisley-Cox, J., Coupland, C., Brindle, P., Derivation and validation of QStroke score for predicting risk of ischaemic stroke in primary care and comparison with other risk scores: a prospective open cohort study. BMJ, 346, 2013, f2573.
57. 57 Dzeshka, M.S., Lane, D.A., Lip, G.Y., Stroke and bleeding risk in atrial fibrillation: navigating the alphabet soup of risk-score acronyms (CHADS2, CHA2DS2-VASc, R2CHADS2, HAS-BLED, ATRIA, and more). Clin Cardiol 37 (2014), 634–644.
58. 58 Singer, D.E., Chang, Y., Borowsky, L.H., et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc, 2, 2013, e000250.
59. 59 Pisters, R., Lane, D.A., Nieuwlaat, R., de Vos, C.B., Crijns, H.J., Lip, G.Y., A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138 (2010), 1093–1100.
60. 60 Gage, B.F., Yan, Y., Milligan, P.E., et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 151 (2006), 713–719.
61. 61 Fang, M.C., Go, A.S., Chang, Y., et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 58 (2011), 395–401.
62. 62 Rodger, M.A., Kahn, S.R., Wells, P.S., et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 179 (2008), 417–426.
63. 63 Eichinger, S., Heinze, G., Jandeck, L.M., Kyrle, P.A., Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation 121 (2010), 1630–1636.
64. 64 Tosetto, A., Iorio, A., Marcucci, M., et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost 10 (2012), 1019–1025.
65. 65 Poli, D., Palareti, G., Assessing recurrence risk following acute venous thromboembolism: use of algorithms. Curr Opin Pulm Med 19 (2013), 407–412.
66. 66 Wells, P.S., Forgie, M.A., Simms, M., et al. The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. Arch Intern Med 163 (2003), 917–920.
67. 67 Burgess, S., Crown, N., Louzada, M.L., Dresser, G., Kim, R.B., Lazo-Langner, A., Clinical performance of bleeding risk scores for predicting major and clinically relevant non-major bleeding events in patients receiving warfarin. J Thromb Haemost 11 (2013), 1647–1654.
68. 68 Molina, C.A., Selim, M.H., The dilemma of resuming anticoagulation after intracranial hemorrhage: little evidence facing big fears. Stroke 42 (2011), 3665–3666.
69. 69 Ment, J., Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation. Vasc Health Risk Manag 11 (2015), 317–332.
70. 70 Milling, T.J. Jr., Refaai, M.A., Goldstein, J.N., et al. Thromboembolic events after vitamin K antagonist reversal with 4-factor prothrombin complex concentrate: exploratory analyses of two randomized, plasma-controlled studies. Ann Emerg Med 67:1 (2016), 96–105.e5.